Review - Haymarket Media Group

CaseStudy
References
1. Zhou P, Recht A. Young age and outcome for women with
early-stage invasive breast carcinoma. Cancer. 2004;101:1264-
1274.
2. Recht A. Lessons of studies of breast-conserving therapy with
and without whole-breast irradiation for patient selection for
partial-breast irradiation. Semin Radiat Oncol. 2005;15:123-132.
3. Schnitt SJ, Connolly JL. Processing and evaluation of breast
excision specimens. A clinically oriented approach. Am J Clin
Pathol. 1992;98:125-137.
4. Recht A. Breast Cancer: Stages T1 and T2. In: Gunderson LL,
Tepper JE, eds. Clinical Radiation Oncology. 2nd ed.
Philadelphia, PA: Churchill Livingstone; 2007:1475-1502.
5. Neuschatz AC, DiPetrillo T, Safaii H, et al. Long-term followup
of a prospective policy of margin-directed radiation dose
escalation in breast-conserving therapy. Cancer. 2003;97:30-39.
6. Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after
breast-conserving surgery and radiation therapy for invasive
breast cancer: influence of margin status and systemic therapy
on local recurrence. J Clin Oncol. 2000;18:1668-1675.
7. Goldstein NS, Kestin L, Vicini F. Factors associated with ipsilateral
breast failure and distant metastases in patients with
invasive breast carcinoma treated with breast-conserving therapy.
A clinicopathologic study of 607 neoplasms from 583
patients. Am J Clin Pathol. 2003;120:500-527.
8. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of
human breast tumours. Nature. 2000;406:747-752.
9. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns
of breast carcinomas distinguish tumor subclasses with
clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-
10874.
10. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification
and molecular forecasting of breast cancer: ready for clinical
application? J Clin Oncol. 2005;23:7350-7360.
26 The American Journal of Hematology/Oncology
11. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of
breast tumor subtypes in independent gene expression data
sets. Proc Natl Acad Sci U S A. 2003;100:8418-8423.
12. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification
and prognosis based on gene expression profiles from a
population-based study. Proc Natl Acad Sci U S A. 2003;100:
10393-10398.
13. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes,
and survival in the Carolina Breast Cancer Study. JAMA.
2006;295:2492-2502.
14. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype
approximated by estrogen receptor, progesterone receptor, and
HER-2 is associated with local and distant recurrence after
breast-conserving therapy. J Clin Oncol. 2008;26:2373-2378.
15. Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor,
progesterone receptor, HER-2, and response to postmastectomy
radiotherapy in high-risk breast cancer: the Danish Breast
Cancer Cooperative Group. J Clin Oncol. 2008;26:1419-1426.
16. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.
Trastuzumab after adjuvant chemotherapy in HER2-positive
breast cancer. N Engl J Med. 2005;353:1659-1672.
17. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer.
N Engl J Med. 2005;353:1673-1684.
Author disclosures: No relationships with industry were reported.
Correspondence address: Paul L. Nguyen, MD, Harvard
Radiation Oncology Program, 75 Francis Street, L2, Boston,
MA 02115; phone: (617) 732-6310; e-mail: pnguyen@
LROC.harvard.edu.
Committed to bringing you the latest and most relevant information in cancer management.
Look in an upcoming issue for a review by Dr Giorgio Zavagno
of his recent article:
INVITED PRESENTATIONS OF PEER-REVIEWED CLINICAL RESEARCH ®
Role of resection margins in patients treated with breast conservation surgery. Cancer. 2008;
112:1923-1931.
Commentary by Drs Laurie Kirstein and David August.
®